Active — Not RecruitingNot Applicable

Screening for Amyloidosis Before Aortic Valve Elective Replacement

Germany1,000 participantsStarted 2021-02-01

Plain-language summary

Previous studies detected that up to 15% of patients undergoing aortic valve replacement (AVR) for degenerative aortic stenosis have concomitant transthyretin amyloidosis (ATTR) cardiomyopathy (Castano, 2017). The aim of this study is to investigate the effectivity and practicability of a systematic ATTR-Screening in patients undergoing planned AVR. Moreover, we plan to develop a screening algorithm to detect ATTR in aortic stenosis (AS).

Who can participate

Age range40 Years – 99 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * age ≥40 years * written informed consent from the patient or of his/her legal guardian * hospitalization for AVR due to degenerative aortic valve stenosis Exclusion Criteria: * hemodynamically unstable patient * severe co-morbidities with an estimated life expectancy of \<1 year

What they're measuring

Number/ proportion of ATTR cases identified by systematic screening

Timeframe: Enrolment period: 18 months

Trial details

NCT IDNCT04869631

SponsorCharite University, Berlin, Germany

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-03-31

View on ClinicalTrials.gov More Amyloidosis trials